Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Conditions
Interventions
DT2216
Paclitaxel
Locations
3
United States
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Start Date
September 22, 2025
Primary Completion Date
December 30, 2026
Completion Date
December 30, 2027
Last Updated
April 21, 2026
NCT06257264
NCT05969860
NCT06547840
NCT05080946
NCT06503146
NCT07498829
Lead Sponsor
Elizabeth Stover, MD, PhD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions